Overview

A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar (sorafenib) in Healthy Volunteers

Status:
COMPLETED
Trial end date:
2025-03-10
Target enrollment:
Participant gender:
Summary
The study aims to assess the pharmacokinetics and safety of DPH001, an amorphous formulation of sorafenib, compared to Nexavar in healthy volunteers.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Disruptive Pharma
Collaborator:
CTC Clinical Trial Consultants AB
Treatments:
Sorafenib